US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
WATERTOWN, Mass. - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biotechnology company with a market capitalization of $1.93 billion, announced today positive outcomes from its Phase 1 study of KT-621, an oral STAT6 degrader, marking a significant advancement in its drug development program. The clinical trial met its primary objective, demonstrating over 90% mean STAT6 degradation in blood at doses above 1.5 mg and complete degradation in blood and skin at doses equal to or greater than 50 mg. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet.
The study, which enrolled 118 healthy volunteers, aimed to assess the safety and tolerability of escalating doses of KT-621. Results indicated that KT-621 was well-tolerated, with a safety profile comparable to placebo, and without any serious adverse events or treatment-related adverse events in more than one subject.
Additionally, the trial observed a median reduction of Th2 biomarkers, including up to 37% in TARC and 63% in Eotaxin-3, which are comparable or superior to those seen with dupilumab, a current treatment for allergic diseases. The reductions in these biomarkers suggest KT-621’s potential efficacy for IL-4/IL-13-driven allergic diseases.
Kymera’s ongoing BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients is actively recruiting, with results expected in the fourth quarter of 2025. The company also plans to initiate two parallel Phase 2b trials in AD and asthma by the end of 2025 and early 2026, respectively. With a healthy current ratio of 8.49 and eight analysts recently revising earnings estimates upward, InvestingPro analysis suggests the company is well-positioned to fund its development pipeline. The stock currently appears undervalued according to InvestingPro’s Fair Value model.
Dr. Nello Mainolfi, CEO of Kymera, expressed confidence in the results, which surpassed the company’s target product profile for KT-621. The data supports the potential of KT-621 to offer a convenient oral therapy with the efficacy similar to injectable biologics for patients with Th2-mediated diseases.
KT-621 is the first STAT6-targeted medicine to enter clinical evaluation, and its development could transform treatment paradigms for millions of patients suffering from a range of Th2 diseases, such as asthma and AD.
This report is based on a press release statement from Kymera Therapeutics, Inc. The company will further discuss the findings in a video conference call and webcast today at 8:00 a.m. ET. For investors seeking deeper insights, InvestingPro offers comprehensive analysis of KYMR’s financial health, including 8 additional ProTips and a detailed research report available exclusively to subscribers.
In other recent news, Kymera Therapeutics announced it will release Phase 1 trial results for its oral STAT6 degrader, KT-621, in June 2025. This trial, involving healthy volunteers, aims to assess the safety and tolerability of KT-621, which has shown promising preclinical results in asthma models. The company is also conducting a Phase 1b trial in patients with atopic dermatitis, with results expected by the end of 2025. Stifel analysts have reinstated coverage of Kymera Therapeutics with a Buy rating and a price target of $55, highlighting the potential of KT-621 to match the efficacy of Dupixent in treating atopic dermatitis. Truist Securities maintains a Buy rating with a $35 target, following the company’s first-quarter business update introducing KT-579, an oral degrader targeting the IRF5 protein. BTIG analyst Jeet Mukherjee adjusted the price target to $55 from $60, maintaining a Buy rating after Kymera’s decision to discontinue its TYK2 degrader program. This strategic shift is expected to extend the company’s cash runway into the first half of 2028. Kymera’s focus remains on advancing KT-621 and the IRF5 program, positioning the company for future developments in treating inflammatory and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.